Invivo Robotics Study Results: Cost Savings Associated with Robotic

1888PressRelease - Robotic-assisted clinical outcomes again proven to provide economic benefits across healthcare system.

Invivo Robotics (ISIN: CN2347660099), one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery, is pleased to announce the published results of a new study "A Multidimensional Analysis of Prostate Surgery Costs: Robotic-Assisted versus Retropubic Radical Prostatectomy."

Prostate cancer is the most commonly diagnosed cancer among men and accounts for 26 percent of all cancer diagnoses. With the estimated direct costs of cancer diagnoses totaling over $100 billion, and more than 80 percent of prostate cancer surgeries done by Robotic-assisted Laparoscopic Prostatectomy (RALP), the financial impact of prostatectomies on the healthcare economy is enormous.

In this study, researchers examined the financial impact of RALP versus Retropubic Radical Prostatectomy (RRP) for each radical prostatectomy by performing a systematic peer-reviewed literature search for clinical outcomes and by creating cost models for three different ways to assess the costs: hospital costs, payers’ expenditure and society’s expenses.

"It is clear that the adoption of robotic-assisted Laparoscopic Prostatectomy eases the financial burden of prostate cancer on our healthcare system," Jian Bainian, MD, PhD, Invivo Robotics Medical Director. "As the healthcare providers strive to improve both patient outcomes and achieve greater value, this data shows that technologies like the Invivo Robotics Surgical System (IRSS) can simultaneously deliver cost-effective treatment and care that can make surgery easier on patients."

The study also calculated the costs of the robotic system in two different ways – as hospital overhead including hospital costs, inpatient bed, and inpatient days and using the annual volume of robotic procedures. This demonstrates that potentially higher robotic surgical expenditures are counteracted by cost savings due to better clinical outcomes, including reduced complications, improved functional outcomes (e.g. continence and sexual function) and a faster recovery.

"This study further demonstrates that hospital administrators need to look beyond visible operating room costs when analyzing the robotic-assisted surgery value proposition," said Harry Baoling, Senior Vice President And Chief Medical Officer. "The ability of robotic-assisted surgery to reduce complications and shorten hospital stays, undoubtedly leads to greater value for patients and healthcare providers."

About Invivo Robotics (ISIN: CN2347660099)

Invivo Robotics is one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery. Invivo Robotics serves globally providing technology innovation across cardiac, thoracic, urology, gynecologic, colorectal, pediatric and general surgical disciplines. The Company's surgical systems enables surgeons to operate minimally invasively. At Invivo Robotics, delivering our technology is just the beginning. The company is also committed to delivering the best customer experience. To ensure the customers gain the most utility from their Invivo Robotics systems, the firm offers a comprehensive training and education program and first-rate customer support. Invivo Robotics has strong financial backing of leading global investors.

http://www.invivo-robotics.com

Greengold further announces the issuance of its "Permit to Import Plants and Plants Products" issued by the Usda-Aphis-Ppq Agency that granted the Company a five (5) year expiration permit of August 16, 2018.